{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:47Z","timestamp":1792783307493,"version":"4.5.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Health","award":["NHLBI\/NIH (R01HL15854601)"],"award-info":[{"award-number":["NHLBI\/NIH (R01HL15854601)"]}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Career Development Award (20CDA3560123)"],"award-info":[{"award-number":["Career Development Award (20CDA3560123)"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12272-023-01447-0","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T04:09:51Z","timestamp":1681790991000},"page":"361-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities"],"prefix":"10.1007","volume":"46","author":[{"given":"Ritwik","family":"Maiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-425X","authenticated-orcid":false,"given":"Bhumika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nrupesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Dhanesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"1447_CR1","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, Johari B, Zali MR, Bagheri N (2019) Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol 234:5628\u20135642. https:\/\/doi.org\/10.1002\/jcp.27419","journal-title":"J Cell Physiol"},{"key":"1447_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"S Ackerman","year":"2021","unstructured":"Ackerman S, Pearson C, Gregorio J, Gonzalez J, Kenkel J, Hartmann F, Luo A, Ho P, LeBlanc H, Blum L, Kimmey S, Luo A, Nguyen M, Paik J, Sheu L, Ackerman B, Lee A, Li H, Melrose J, Laura R, Ramani V, Henning K, Jackson D, Safina B, Yonehiro G, Devens B, Carmi Y, Chapin S, Bendall S, Kowanetz M, Dornan D, Engleman E, Alonso M (2021) Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer 2:18\u201333. https:\/\/doi.org\/10.1038\/s43018-020-00136-x","journal-title":"Nat Cancer"},{"key":"1447_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1517\/14712598.2012.693473","volume":"12","author":"JR Adair","year":"2012","unstructured":"Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA (2012) Antibody\u2013drug conjugates\u2014a perfect synergy. Expert Opin Biol Ther 12:1191\u20131206. https:\/\/doi.org\/10.1517\/14712598.2012.693473","journal-title":"Expert Opin Biol Ther"},{"key":"1447_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11307-015-0919-4","volume":"18","author":"P Adumeau","year":"2016","unstructured":"Adumeau P, Sharma SK, Brent C, Zeglis B (2016) Site-specifically labeled immunoconjugates for molecular imaging\u2014part 1: cysteine residues and glycans. Mol Imaging Biol 18:1\u201317. https:\/\/doi.org\/10.1007\/s11307-015-0919-4","journal-title":"Mol Imaging Biol"},{"key":"1447_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/bc5004982","volume":"26","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bertozzi CR (2015) Site-specific antibody\u2013drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem 26:176\u2013192. https:\/\/doi.org\/10.1021\/bc5004982","journal-title":"Bioconjug Chem"},{"key":"1447_CR6","first-page":"3541","volume":"53","author":"N Albin","year":"1993","unstructured":"Albin N, Massaad L, Toussaint C, Mathieu M-C, Morizet J, Parise O, Gouyette A, Chabot GG (1993) Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 53:3541\u20133546","journal-title":"Cancer Res"},{"key":"1447_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cbpa.2013.03.022","volume":"17","author":"SC Alley","year":"2013","unstructured":"Alley SC, Anderson KE (2013) Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. Curr Opin Chem Biol 17:406\u2013411","journal-title":"Curr Opin Chem Biol"},{"key":"1447_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12254-021-00780-8","volume":"15","author":"M-B Aretin","year":"2022","unstructured":"Aretin M-B (2022) Antibody\u2013drug conjugates\u2014the magic bullet? Memo-magazine. Eur Med Oncol 15:125\u2013128. https:\/\/doi.org\/10.1007\/s12254-021-00780-8","journal-title":"Eur Med Oncol"},{"key":"1447_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer I, Vahdat L, Tolaney S, Isakoff S, Diamond J, O\u2019Shaughnessy J, Moroose R, Santin A, Abramson V, Shah N, Rugo H, Goldenberg D, Sweidan A, Iannone R, Washkowitz S, Sharkey R, Wegener W, Kalinsky K (2019) Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380:741\u2013751. https:\/\/doi.org\/10.1056\/NEJMoa1814213","journal-title":"N Engl J Med"},{"key":"1447_CR10","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev 48:4361\u20134374. https:\/\/doi.org\/10.1039\/C8CS00676H","journal-title":"Chem Soc Rev"},{"key":"1447_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast cancer Res 16:1\u201312. https:\/\/doi.org\/10.1186\/bcr3621","journal-title":"Breast cancer Res"},{"key":"1447_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","volume":"16","author":"A Beck","year":"2019","unstructured":"Beck A, D\u2019atri V, Ehkirch A, Fekete S, Hernandez-Alba O, Gahoual R, Leize-Wagner E, Francois Y, Guillarme D, Cianf\u00e9rani S (2019) Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Rev Proteomics 16:337\u2013362. https:\/\/doi.org\/10.1080\/14789450.2019.1578215","journal-title":"Expert Rev Proteomics"},{"key":"1447_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-319-46877-8_5","volume-title":"Enzyme-based strategies to Generate Site-Specifically conjugated antibody drug conjugates BT - Next generation antibody drug conjugates (ADCs) and immunotoxins","author":"RR Beerli","year":"2017","unstructured":"Beerli RR, Grawunder U (2017) In: Grawunder U, Barth S (eds) Enzyme-based strategies to Generate Site-Specifically conjugated antibody drug conjugates BT - Next generation antibody drug conjugates (ADCs) and immunotoxins. Springer International Publishing, Cham, pp 85\u2013106"},{"key":"1447_CR14","unstructured":"Beusker PF. \u201cMagic bullets\u201d to \u201cTrojan-Horses\u201d: the evolution of next-generation antibody-drug conjugates. https:\/\/www.byonids.com\/who-we-are\/blogs\/2022-03-28. Accessed 5 Aug 2022"},{"key":"1447_CR15","unstructured":"BiopharmPEG 9 types of drug conjugates overview : ADC, RDC, ISAC, SMDC, AOC\u2026 https:\/\/www.biochempeg.com\/article\/266.html. Accessed 30 Aug 2022"},{"key":"1447_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jpba.2017.06.022","volume":"147","author":"B Bob\u00e1ly","year":"2018","unstructured":"Bob\u00e1ly B, Fleury-Souverain S, Beck A, Veuthey J-L, Guillarme D, Fekete S (2018) Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates. J Pharm Biomed Anal 147:493\u2013505. https:\/\/doi.org\/10.1016\/j.jpba.2017.06.022","journal-title":"J Pharm Biomed Anal"},{"key":"1447_CR17","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","volume":"15","author":"JW Buecheler","year":"2018","unstructured":"Buecheler JW, Winzer M, Tonillo J, Weber C, Gieseler H (2018) Impact of payload hydrophobicity on the stability of antibody\u2013drug conjugates. Mol Pharm 15:2656\u20132664. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00177","journal-title":"Mol Pharm"},{"key":"1447_CR18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/ph13120462","volume":"13","author":"H Cahuzac","year":"2020","unstructured":"Cahuzac H, Devel L (2020) Analytical methods for the detection and quantification of ADCs in biological matrices. Pharmaceuticals 13:462. https:\/\/doi.org\/10.3390\/ph13120462","journal-title":"Pharmaceuticals"},{"key":"1447_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/ppo.0b013e318172d704","volume":"14","author":"PJ Carter","year":"2008","unstructured":"Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154\u2013169. https:\/\/doi.org\/10.1097\/ppo.0b013e318172d704","journal-title":"Cancer J"},{"key":"1447_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1573394712666160805121312","volume":"12","author":"J-F Chatal","year":"2016","unstructured":"Chatal J-F, Kraeber-Bod\u00e9r\u00e9 F, Bodet-milin C, Rousseau C (2016) Therapeutic immunoconjugates. Which cytotoxic payload: chemotherapeutic drug (ADC) or Radionuclide (ARC) ? Curr Cancer Ther Rev 12:54\u201365. https:\/\/doi.org\/10.2174\/1573394712666160805121312","journal-title":"Curr Cancer Ther Rev"},{"key":"1447_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD (2019) Antibody drug conjugates for cancer. Lancet 394:793\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(19)31774-X","journal-title":"Lancet"},{"key":"1447_CR22","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1021\/acs.analchem.8b04699","volume":"91","author":"T-H Chen","year":"2019","unstructured":"Chen T-H, Yang Y, Zhang Z, Fu C, Zhang Q, Williams JD, Wirth MJ (2019) Native reversed-phase liquid chromatography: a technique for LCMS of intact antibody\u2013drug conjugates. Anal Chem 91:2805\u20132812. https:\/\/doi.org\/10.1021\/acs.analchem.8b04699","journal-title":"Anal Chem"},{"key":"1447_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G (2021) Antibody\u2013drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 14:20. https:\/\/doi.org\/10.1186\/s13045-021-01035-z","journal-title":"J Hematol Oncol"},{"key":"1447_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/17474086.2016.1143771","volume":"9","author":"J Dahl","year":"2016","unstructured":"Dahl J, Marx K, Jabbour E (2016) Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol 9:329\u2013334. https:\/\/doi.org\/10.1586\/17474086.2016.1143771","journal-title":"Expert Rev Hematol"},{"key":"1447_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2174\/1381612023394485","volume":"8","author":"M de Graaf","year":"2002","unstructured":"de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM (2002) Beta-glucuronidase-mediated drug release. Curr Pharm Des 8:1391\u20131403","journal-title":"Curr Pharm Des"},{"key":"1447_CR26","first-page":"1951427","volume-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","author":"AQ Dean","year":"2021","unstructured":"Dean AQ, Luo S, Twomey JD, Zhang B (2021) In: MAbs (ed) Targeting cancer with antibody-drug conjugates: promises and challenges. Taylor & Francis, p 1951427"},{"key":"1447_CR27","unstructured":"Debiopharm Debiopharm and Ubix (2022) Therapeutics launch research to develop a new anti-cancer modality\u2014antibody degraducer\u00ae conjugates. https:\/\/www.debiopharm.com\/drug-development\/press-releases\/debiopharm-and-ubix-therapeutics-launch-research-to-develop-a-new-anti-cancer-modality-antibody-degraducer-conjugates\/"},{"key":"1447_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/bc400574z","volume":"25","author":"P Dennler","year":"2014","unstructured":"Dennler P, Chiotellis, Aristeidis, Fischer E, Br\u00e9geon D, Belmant C, Gauthier L, Lhospice F, Romagne F, Schibli R (2014) Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody\u2013drug conjugates. Bioconjug Chem 25:569\u2013578. https:\/\/doi.org\/10.1021\/bc400574z","journal-title":"Bioconjug Chem"},{"key":"1447_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/antib4030197","volume":"4","author":"P Dennler","year":"2015","unstructured":"Dennler P, Fischer E, Schibli R (2015) Antibody conjugates: from heterogeneous populations to defined reagents. Antibodies 4:197\u2013224. https:\/\/doi.org\/10.3390\/antib4030197","journal-title":"Antibodies"},{"key":"1447_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1517\/17460441.2015.1025049","volume":"10","author":"MP Deonarain","year":"2015","unstructured":"Deonarain MP, Yahioglu G, Stamati I, Marklew J (2015) Emerging formats for next-generation antibody drug conjugates. Expert Opin Drug Discov 10:463\u2013481. https:\/\/doi.org\/10.1517\/17460441.2015.1025049","journal-title":"Expert Opin Drug Discov"},{"key":"1447_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","volume":"54","author":"JF DiJoseph","year":"2005","unstructured":"DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann PR, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK (2005) Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 54:11\u201324. https:\/\/doi.org\/10.1007\/s00262-004-0572-2","journal-title":"Cancer Immunol Immunother"},{"key":"1447_CR32","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go M, Jack A, Junutula J, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu S, Yue P, Zheng B, Ebens A, Polson A (2009) Therapeutic potential of an anti-CD79b antibody\u2013drug conjugate, anti\u2013CD79b-vc-MMAE, for the treatment of non-hodgkin lymphoma. Blood 114:2721\u20132729. https:\/\/doi.org\/10.1182\/blood-2009-02-205500","journal-title":"Blood"},{"key":"1447_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt0803-941a","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Erratum: development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:941. https:\/\/doi.org\/10.1038\/nbt0803-941a","journal-title":"Nat Biotechnol"},{"key":"1447_CR34","doi-asserted-by":"publisher","first-page":"e0132282","DOI":"10.1371\/journal.pone.0132282","volume":"10","author":"M Dorywalska","year":"2015","unstructured":"Dorywalska M, Strop P, Melton-Witt J, Hasa-Moreno A, Farias S, Galindo Casas M, Delaria K, Lui V, Poulsen K, Sutton J, Bolton G, Zhou D, Moine L, Dushin R, Tran T, Liu S, Rickert M, Foletti D, Shelton D, Rajpal A (2015) Site-dependent degradation of a non-cleavable auristatin-based linker-payload in Rodent plasma and its effect on ADC efficacy. PLoS ONE 10:e0132282. https:\/\/doi.org\/10.1371\/journal.pone.0132282","journal-title":"PLoS ONE"},{"key":"1447_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40290-018-0238-6","volume":"32","author":"J Dott","year":"2018","unstructured":"Dott J, Abila B, Wuerthner JU (2018) Current trends in the clinical development of antibody-drug conjugates in oncology. Pharma Med 32:259\u2013273. https:\/\/doi.org\/10.1007\/s40290-018-0238-6","journal-title":"Pharma Med"},{"key":"1447_CR36","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","volume":"30","author":"I Dovgan","year":"2019","unstructured":"Dovgan I, Koniev O, Kolodych S, Wagner A (2019) Antibody\u2013Oligonucleotide Conjugates as Therapeutic, Imaging, and detection agents. Bioconjug Chem 30:2483\u20132501. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00306","journal-title":"Bioconjug Chem"},{"key":"1447_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1096\/fj.05-4739com","volume":"21","author":"D Drenkard","year":"2007","unstructured":"Drenkard D, Becke F, Langstein J, Spruss T, Kunz-Schughart L, Tan T, Lim Y, Schwarz H (2007) CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J 21:456\u2013463. https:\/\/doi.org\/10.1096\/fj.05-4739com","journal-title":"FASEB J"},{"key":"1447_CR38","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1021\/acs.jnatprod.7b00359","volume":"80","author":"J Dugal-Tessier","year":"2017","unstructured":"Dugal-Tessier J, Barnscher S, Kanai A, Mendelsohn B (2017) Synthesis and evaluation of Dolastatin 10 Analogues containing heteroatoms on the amino acid side chains. J Nat Prod 80:2484\u20132491. https:\/\/doi.org\/10.1021\/acs.jnatprod.7b00359","journal-title":"J Nat Prod"},{"key":"1447_CR39","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/jcm10040838","volume":"10","author":"J Dugal-Tessier","year":"2021","unstructured":"Dugal-Tessier J, Thirumalairajan S, Jain N (2021) Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates. J Clin Med 10:838. https:\/\/doi.org\/10.3390\/jcm10040838","journal-title":"J Clin Med"},{"key":"1447_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antib7010004","volume":"7","author":"G Falck","year":"2018","unstructured":"Falck G, M\u00fcller KM (2018) Enzyme-based labeling strategies for antibody\u2013drug conjugates and antibody mimetics. Antibodies 7:4. https:\/\/doi.org\/10.3390\/antib7010004","journal-title":"Antibodies"},{"key":"1447_CR41","doi-asserted-by":"publisher","first-page":"15396","DOI":"10.1021\/bi051460d","volume":"44","author":"Q Fang","year":"2005","unstructured":"Fang Q, Kanugula S, Pegg AE (2005) Function of domains of human O6-Alkylguanine-DNA alkyltransferase. Biochemistry 44:15396\u201315405. https:\/\/doi.org\/10.1021\/bi051460d","journal-title":"Biochemistry"},{"key":"1447_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jconrel.2021.12.013","volume":"341","author":"SW Fatima","year":"2022","unstructured":"Fatima SW, Khare SK (2022) Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J Control Release 341:555\u2013565. https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.013","journal-title":"J Control Release"},{"key":"1447_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines2010001","volume":"2","author":"Y Feng","year":"2014","unstructured":"Feng Y, Zhu Z, Chen W, Prabakaran P, Lin K, Dimitrov DS (2014) Conjugates of small molecule drugs with antibodies and other proteins. Biomedicines 2:1\u201313","journal-title":"Biomedicines"},{"key":"1447_CR44","doi-asserted-by":"publisher","first-page":"E1176","DOI":"10.1073\/pnas.1315776111","volume":"111","author":"JO Fierer","year":"2014","unstructured":"Fierer JO, Veggiani G, Howarth M (2014) SpyLigase peptide\u2013peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture. Proc Natl Acad Sci 111:E1176\u2013E1181. https:\/\/doi.org\/10.1073\/pnas.1315776111","journal-title":"Proc Natl Acad Sci"},{"key":"1447_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-8722-5-70","volume":"5","author":"MA Firer","year":"2012","unstructured":"Firer MA, Gellerman G (2012) Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 5:70. https:\/\/doi.org\/10.1186\/1756-8722-5-70","journal-title":"J Hematol Oncol"},{"key":"1447_CR46","doi-asserted-by":"publisher","unstructured":"Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M (2022a) Peptide\u2013drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B In Press. https:\/\/doi.org\/10.1016\/j.apsb.2022.07.020","DOI":"10.1016\/j.apsb.2022.07.020"},{"key":"1447_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022b) Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther 7:1\u201325. https:\/\/doi.org\/10.1038\/s41392-022-00947-7","journal-title":"Signal Transduct Target Ther"},{"key":"1447_CR48","doi-asserted-by":"crossref","unstructured":"Fujii T, Matsuda Y, Seki T, Shikida N, Iwai Y, Ooba Y, Takahashi K, Isokawa M, Kawaguchi S, Hatada N (2023) AJICAP second generation: improved chemical site-specific conjugation technology for antibody-drug conjugate production","DOI":"10.26434\/chemrxiv-2023-9p5p7"},{"key":"1447_CR49","doi-asserted-by":"crossref","unstructured":"Garbaccio RM (2014) Chemistry of antibody\u2013small molecule drug conjugates. In: Chemical linkers in antibody-drug conjugates (ADCs). Elsevier","DOI":"10.1016\/B978-0-08-097742-3.00942-3"},{"key":"1447_CR50","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","volume":"78","author":"S Garcia-Alonso","year":"2018","unstructured":"Garcia-Alonso S, Ocana A, Pandiella A (2018) Resistance to antibody\u2013drug conjugates. Cancer Res 78:2159\u20132165. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3671","journal-title":"Cancer Res"},{"key":"1447_CR51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/2472555220912955","volume":"25","author":"L Gauzy-Lazo","year":"2020","unstructured":"Gauzy-Lazo L, Sassoon I, Brun M-P (2020) Advances in antibody\u2013drug conjugate design: current clinical landscape and future innovations. SLAS Discov Adv Sci Drug Discov 25:843\u2013868. https:\/\/doi.org\/10.1177\/2472555220912955","journal-title":"SLAS Discov Adv Sci Drug Discov"},{"key":"1447_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clon.2004.11.011","volume":"17","author":"AM Gaya","year":"2005","unstructured":"Gaya AM, Rustin GJS (2005) Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol 17:277\u2013290. https:\/\/doi.org\/10.1016\/j.clon.2004.11.011","journal-title":"Clin Oncol"},{"key":"1447_CR53","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1039\/c3np20113a","volume":"30","author":"H-P Gerber","year":"2013","unstructured":"Gerber H-P, Koehn F, Abraham R (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30:625\u2013639. https:\/\/doi.org\/10.1039\/c3np20113a","journal-title":"Nat Prod Rep"},{"key":"1447_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/978-1-4939-9546-2_17","volume":"2012","author":"M Gerlach","year":"2019","unstructured":"Gerlach M, Stoschek T, Leonhardt H, Hackenberger CPR, Schumacher D, Helma J (2019) Tubulin tyrosine ligase-mediated modification of proteins. Methods Mol Biol 2012:327\u2013355. https:\/\/doi.org\/10.1007\/978-1-4939-9546-2_17","journal-title":"Methods Mol Biol"},{"key":"1447_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00280-012-1925-8","volume":"70","author":"DA Gianolio","year":"2012","unstructured":"Gianolio DA, Rouleau C, Bauta WE, Lovett D, Cantrell WR, Recio A, Wolstenholme-Hogg P, Busch M, Pan P, Stefano JE, Kramer HM, Goebel J, Krumbholz RD, Roth S, Schmid SM, Teicher BA (2012) Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody\u2013drug conjugates. Cancer Chemother Pharmacol 70:439\u2013449. https:\/\/doi.org\/10.1007\/s00280-012-1925-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"1447_CR56","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","volume":"11","author":"D Goldenberg","year":"2019","unstructured":"Goldenberg D, Sharkey R (2019) Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs 11:987\u2013995. https:\/\/doi.org\/10.1080\/19420862.2019.1632115","journal-title":"MAbs"},{"key":"1447_CR57","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4155\/tde.10.98","volume":"2","author":"VS Goldmacher","year":"2011","unstructured":"Goldmacher VS, Kovtun YV (2011) Antibody\u2013drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2:397\u2013416. https:\/\/doi.org\/10.4155\/tde.10.98","journal-title":"Ther Deliv"},{"key":"1447_CR58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jddst.2018.08.022","volume":"48","author":"N Goli","year":"2018","unstructured":"Goli N, Bolla PK, Talla V (2018) Antibody-drug conjugates (ADCs): potent biopharmaceuticals to target solid and hematological cancers- an overview. J Drug Deliv Sci Technol 48:106\u2013117. https:\/\/doi.org\/10.1016\/j.jddst.2018.08.022","journal-title":"J Drug Deliv Sci Technol"},{"key":"1447_CR59","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1021\/acs.oprd.2c00227","volume":"26","author":"WRF Goundry","year":"2022","unstructured":"Goundry WRF, Parker JS (2022) Payloads for antibody\u2013drug conjugates. Org Process Res Dev 26:2121\u20132123","journal-title":"Org Process Res Dev"},{"key":"1447_CR60","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/14712598.2016.1173203","volume":"16","author":"SV Govindan","year":"2016","unstructured":"Govindan SV, Sharkey RM, Goldenberg DM (2016) Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opin Biol Ther 16:883\u2013893. https:\/\/doi.org\/10.1517\/14712598.2016.1173203","journal-title":"Expert Opin Biol Ther"},{"key":"1447_CR61","doi-asserted-by":"crossref","unstructured":"Govindan SV, Cardillo TM, Goldenberg DM (2019) Topoisomerase inhibitors as antibody\u2013drug conjugate (ADC) payloads. In: Thurston DE, Jackson P (ed) Cytotoxic payloads for antibody\u2013drug conjugates, p\u00a0166\u2013186","DOI":"10.1039\/9781788012898-00166"},{"key":"1447_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchromb.2017.09.027","volume":"1065","author":"A Goyon","year":"2017","unstructured":"Goyon A, D\u2019Atri V, Colas O, Fekete S, Beck A, Guillarme D (2017) Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: feasibility assessment for future mass spectrometry hyphenation. J Chromatogr B 1065:35\u201343. https:\/\/doi.org\/10.1016\/j.jchromb.2017.09.027","journal-title":"J Chromatogr B"},{"key":"1447_CR63","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/acs.bioconjchem.5b00682","volume":"27","author":"N Griebenow","year":"2016","unstructured":"Griebenow N, Dilma\u00e7 AM, Greven S, Br\u00e4se S (2016) Site-specific conjugation of peptides and proteins via rebridging of Disulfide Bonds using the thiol\u2013yne coupling reaction. Bioconjug Chem 27:911\u2013917. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00682","journal-title":"Bioconjug Chem"},{"key":"1447_CR64","first-page":"237","volume-title":"Site-specific antibody labeling using Phosphopantetheinyl transferase-catalyzed ligation BT\u2014enzyme-mediated ligation methods","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald J, Brock A, Geierstanger BH (2019). In: Nuijens T, Schmidt M (eds) Site-specific antibody labeling using Phosphopantetheinyl transferase-catalyzed ligation BT\u2014enzyme-mediated ligation methods. Springer, New York, pp 237\u2013278"},{"key":"1447_CR65","first-page":"1269","volume-title":"Case study: irinotecan (CPT-11), a water-soluble prodrug of SN-38 BT\u2014prodrugs: challenges and rewards part 1","author":"MJ Hageman","year":"2007","unstructured":"Hageman MJ, Morozowich W (2007). In: Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW (eds) Case study: irinotecan (CPT-11), a water-soluble prodrug of SN-38 BT\u2014prodrugs: challenges and rewards part 1. Springer, New York, pp 1269\u20131279"},{"key":"1447_CR66","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1039\/D1CC03976H","volume":"57","author":"M Haque","year":"2021","unstructured":"Haque M, Forte N, Baker JR (2021) Site-selective lysine conjugation methods and applications towards antibody\u2013drug conjugates. Chem Commun 57:10689\u201310702. https:\/\/doi.org\/10.1039\/D1CC03976H","journal-title":"Chem Commun"},{"key":"1447_CR67","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1158\/1538-7445.AM2015-647","volume":"75","author":"L Harris","year":"2015","unstructured":"Harris L, Tavares D, Rui L, Maloney E, Wilhelm A, Costoplus J, Archer K, Bogalhas M, Harvey L, Wu R, Chen X, Xu X, Connaughton S, Wang L, Whiteman K, Ab O, Hong E, Widdison W, Shizuka M, Miller M, Pinkas J, Keating T, Chari R, Fishkin N (2015) SeriMabs: N-terminal serine modification enables modular, site-specific payload incorporation into antibody-drug conjugates (ADCs). Cancer Res 75:647. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-647","journal-title":"Cancer Res"},{"key":"1447_CR68","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","volume":"21","author":"JA Hartley","year":"2021","unstructured":"Hartley JA (2021) Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther 21:931\u2013943. https:\/\/doi.org\/10.1080\/14712598.2020.1776255","journal-title":"Expert Opin Biol Ther"},{"key":"1447_CR69","doi-asserted-by":"publisher","first-page":"781800","DOI":"10.3389\/fonc.2021.781800","volume":"11","author":"S Havaei","year":"2021","unstructured":"Havaei S, Aucoin M, Jahanian-Najafabadi A (2021) Pseudomonas Exotoxin-Based immunotoxins: over three decades of efforts on Targeting Cancer cells with the Toxin. Front Oncol 11:781800\u2013781817. https:\/\/doi.org\/10.3389\/fonc.2021.781800","journal-title":"Front Oncol"},{"key":"1447_CR70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fchem.2020.00571","volume":"8","author":"P Hoppenz","year":"2020","unstructured":"Hoppenz P, Els-Heindl S, Beck-Sickinger AG (2020) Peptide-drug conjugates and their targets in Advanced Cancer Therapies. Front Chem 8:571. https:\/\/doi.org\/10.3389\/fchem.2020.00571","journal-title":"Front Chem"},{"key":"1447_CR71","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.drudis.2016.04.004","volume":"21","author":"RYC Huang","year":"2016","unstructured":"Huang RYC, Chen G (2016) Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. Drug Discov Today 21:850\u2013855","journal-title":"Drug Discov Today"},{"key":"1447_CR72","doi-asserted-by":"publisher","first-page":"e14544","DOI":"10.1200\/JCO.2022.40.16_suppl.e14544","volume":"40","author":"RV Huisin\u2019t Veld","year":"2022","unstructured":"Huisin\u2019t Veld RV, Ma S, Kines R, Savinainen A, Rich CC, Ossendorp F, Jager M (2022) A novel virus-like drug conjugate (VDC) in combination with immune checkpoint inhibitors for the treatment of primary tumors and distant metastasis. J Clin Oncol 40:e14544\u2013e14544. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e14544","journal-title":"J Clin Oncol"},{"key":"1447_CR73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/ph14040343","volume":"14","author":"AF Hussain","year":"2021","unstructured":"Hussain AF, Grimm A, Sheng W, Zhang C, Al-Rawe M, Br\u00e4utigam K, Abu Mraheil M, Zeppernick F, Meinhold-Heerlein I (2021) Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches. Pharmaceuticals 14:343. https:\/\/doi.org\/10.3390\/ph14040343","journal-title":"Pharmaceuticals"},{"key":"1447_CR74","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","volume":"32","author":"N Jain","year":"2015","unstructured":"Jain N, Smith SW, Ghone S, Tomczuk B (2015) Current ADC linker chemistry. Pharm Res 32:3526\u20133540. https:\/\/doi.org\/10.1007\/s11095-015-1657-7","journal-title":"Pharm Res"},{"key":"1447_CR75","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1021\/ml100039h","volume":"1","author":"SC Jeffrey","year":"2010","unstructured":"Jeffrey SC, De Brabander J, Miyamoto J, Senter PD (2010) Expanded utility of the \u03b2-Glucuronide linker: ADCs that deliver phenolic cytotoxic agents. ACS Med Chem Lett 1:277\u2013280. https:\/\/doi.org\/10.1021\/ml100039h","journal-title":"ACS Med Chem Lett"},{"key":"1447_CR76","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1124\/pharmrev.121.000499","volume":"74","author":"Y Jin","year":"2022","unstructured":"Jin Y, Edalatian Zakeri S, Bahal R, Wiemer AJ (2022) New Technologies Bloom together for bettering Cancer Drug Conjugates. Pharmacol Rev 74:680\u2013711. https:\/\/doi.org\/10.1124\/pharmrev.121.000499","journal-title":"Pharmacol Rev"},{"key":"1447_CR77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ddtec.2018.10.003","volume":"30","author":"MC Johnston","year":"2018","unstructured":"Johnston MC, Scott CJ (2018) Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy. Drug Discov Today Technol 30:63\u201369. https:\/\/doi.org\/10.1016\/j.ddtec.2018.10.003","journal-title":"Drug Discov Today Technol"},{"key":"1447_CR78","first-page":"1682895","volume-title":"Native size-exclusion chromatography-mass spectrometry: suitability for antibody\u2013drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels","author":"J Jones","year":"2020","unstructured":"Jones J, Pack L, Hunter JH, Valliere-Douglass JF (2020). In: MAbs (ed) Native size-exclusion chromatography-mass spectrometry: suitability for antibody\u2013drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels. Taylor & Francis, p 1682895"},{"key":"1447_CR79","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/ph13090245","volume":"13","author":"N Joubert","year":"2020","unstructured":"Joubert N, Beck A, Dumontet C, Denevault-Sabourin C (2020) Antibody\u2013drug conjugates: the last decade. Pharmaceuticals 13:245. https:\/\/doi.org\/10.3390\/ph13090245","journal-title":"Pharmaceuticals"},{"key":"1447_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska I, Muyldermans S (2020) The therapeutic potential of nanobodies. BioDrugs 34:11\u201326. https:\/\/doi.org\/10.1007\/s40259-019-00392-z","journal-title":"BioDrugs"},{"key":"1447_CR81","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.3390\/ijms21176018","volume":"21","author":"A Juan","year":"2020","unstructured":"Juan A, Cimas FJ, Bravo I, Pandiella A, Oca\u00f1a A, Alonso-Moreno C (2020) Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment. Int J Mol Sci 21:6018. https:\/\/doi.org\/10.3390\/ijms21176018","journal-title":"Int J Mol Sci"},{"key":"1447_CR82","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"J Junutula","year":"2008","unstructured":"Junutula J, Raab H, Clark S, Bhakta S, Leipold D, Weir S, Chen Y, Simpson M, Tsai S, Dennis M, Lu Y, Meng Y, Ng C, Yang J, Lee C, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer S, Lee W, Lowman H, Vandlen R, Sliwkowski M, Scheller R, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925\u2013932. https:\/\/doi.org\/10.1038\/nbt.1480","journal-title":"Nat Biotechnol"},{"key":"1447_CR83","doi-asserted-by":"publisher","first-page":"e004646","DOI":"10.1136\/jitc-2022-004646","volume":"10","author":"DV Kalinovsky","year":"2022","unstructured":"Kalinovsky DV, Kibardin AV, Kholodenko IV, Svirshchevskaya EV, Doronin II, Konovalova MV, Grechikhina MV, Rozov FN, Larin SS, Deyev SM (2022) Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. J Immunother cancer 10:e004646. https:\/\/doi.org\/10.1136\/jitc-2022-004646","journal-title":"J Immunother cancer"},{"key":"1447_CR84","unstructured":"K\u00e4llsten M (2020) Development and evaluation of analytical techniques for antibodies and antibody-drug conjugates: From verification of conjugation to stability testing. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1901, Acta Universitatis Upsaliensis"},{"key":"1447_CR85","doi-asserted-by":"publisher","first-page":"13613","DOI":"10.1039\/D1SC02973H","volume":"12","author":"MS Kang","year":"2021","unstructured":"Kang MS, Kong TWS, Khoo JYX, Loh T-P (2021) Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody\u2013drug conjugates. Chem Sci 12:13613\u201313647. https:\/\/doi.org\/10.1039\/D1SC02973H","journal-title":"Chem Sci"},{"key":"1447_CR86","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1021\/jacs.5b12547","volume":"138","author":"JC Kern","year":"2016","unstructured":"Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, Figueroa I, Hsieh S, Liang L, Tomazela D (2016) Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody\u2013drug conjugates. J Am Chem Soc 138:1430\u20131445. https:\/\/doi.org\/10.1021\/jacs.5b12547","journal-title":"J Am Chem Soc"},{"key":"1447_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.mcr-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J (2020) Antibody-drug conjugates: a comprehensive review. Mol Cancer Res 18:3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.mcr-19-0582","journal-title":"Mol Cancer Res"},{"key":"1447_CR88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40824-021-00244-4","volume":"25","author":"D-H Kim","year":"2021","unstructured":"Kim D-H, Seo J-M, Shin K-J, Yang S-G (2021) Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy. Biomater Res 25:42. https:\/\/doi.org\/10.1186\/s40824-021-00244-4","journal-title":"Biomater Res"},{"key":"1447_CR89","doi-asserted-by":"publisher","first-page":"1914885","DOI":"10.1080\/19420862.2021.1914885","volume":"13","author":"MJ Ko","year":"2021","unstructured":"Ko MJ, Song D, Kim J, Kim JY, Eom J, Sung B, Son Y-G, Kim YM, Lee SH, You W-K, Jung J (2021) N-terminal selective conjugation method widens the therapeutic window of antibody\u2013drug conjugates by improving tolerability and stability. MAbs 13:1914885. https:\/\/doi.org\/10.1080\/19420862.2021.1914885","journal-title":"MAbs"},{"key":"1447_CR90","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/ph14050442","volume":"14","author":"V Kostova","year":"2021","unstructured":"Kostova V, D\u00e9sos P, Starck J-B, Kotschy A (2021) The chemistry behind ADCs. Pharmaceuticals 14:442. https:\/\/doi.org\/10.3390\/ph14050442","journal-title":"Pharmaceuticals"},{"key":"1447_CR91","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun YV, Goldmacher VS (2007) Cell killing by antibody\u2013drug conjugates. Cancer Lett 255:232\u2013240. https:\/\/doi.org\/10.1016\/j.canlet.2007.04.010","journal-title":"Cancer Lett"},{"key":"1447_CR92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1515\/hsz-2018-0358","volume":"400","author":"T Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger T, Dierks T, Sewald N (2019) Formylglycine-generating enzymes for site-specific bioconjugation. Biol Chem 400:289\u2013297. https:\/\/doi.org\/10.1515\/hsz-2018-0358","journal-title":"Biol Chem"},{"key":"1447_CR93","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF00199228","volume":"19","author":"PN Kulkarni","year":"1985","unstructured":"Kulkarni PN, Blair AH, Ghose T, Mammen M (1985) Conjugation of methotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo. Cancer Immunol Immunother 19:211\u2013214. https:\/\/doi.org\/10.1007\/BF00199228","journal-title":"Cancer Immunol Immunother"},{"key":"1447_CR94","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.bmcl.2018.10.043","volume":"28","author":"A Kumar","year":"2018","unstructured":"Kumar A, Kinneer K, Masterson L, Ezeadi E, Howard P, Wu H, Gao C, Dimasi N (2018) Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorg Med Chem Lett 28:3617\u20133621. https:\/\/doi.org\/10.1016\/j.bmcl.2018.10.043","journal-title":"Bioorg Med Chem Lett"},{"key":"1447_CR95","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A (2021) Loncastuximab tesirine: first approval. Drugs 81:1229\u20131233. https:\/\/doi.org\/10.1007\/s40265-021-01550-w","journal-title":"Drugs"},{"key":"1447_CR96","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1038\/onc.2015.514","volume":"35","author":"JM Lee","year":"2016","unstructured":"Lee JM, Lee SH, Hwang J-W, Oh SJ, Kim B, Jung S, Shim S, Lin PW, Lee SB, Cho M-Y, Koh YJ, Kim SY, Ahn S, Lee J, Kim K, Cheong KH, Choi J, Kim K-A (2016) Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene 35:4437\u20134446. https:\/\/doi.org\/10.1038\/onc.2015.514","journal-title":"Oncogene"},{"key":"1447_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201402606","author":"X Li","year":"2014","unstructured":"Li X, Fang T, Boons G-J (2014) Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl. https:\/\/doi.org\/10.1002\/anie.201402606","journal-title":"Angew Chem Int Ed Engl"},{"key":"1447_CR98","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.biosx.2022.100126","volume":"10","author":"P Liu","year":"2022","unstructured":"Liu P, Ga L, Aodeng G, Wang Y, Ai J (2022) Aptamer-drug conjugates: New probes for imaging and targeted therapy. Biosens Bioelectron X 10:100126. https:\/\/doi.org\/10.1016\/j.biosx.2022.100126","journal-title":"Biosens Bioelectron X"},{"key":"1447_CR99","first-page":"583","volume-title":"Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates","author":"L Liu-Shin","year":"2018","unstructured":"Liu-Shin L, Fung A, Malhotra A, Ratnaswamy G (2018). In: MAbs (ed) Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates. Taylor & Francis, pp 583\u2013595"},{"key":"1447_CR100","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber H-P (2016) Mechanisms of resistance to antibody\u2013drug conjugates. Mol Cancer Ther 15:2825\u20132834. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0408","journal-title":"Mol Cancer Ther"},{"key":"1447_CR101","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s12045-022-1409-z","volume":"27","author":"M Lopus","year":"2022","unstructured":"Lopus M (2022) Shooting Cancer with magic bullets. Promises and challenges of antibody-drug conjugates. Resonance 27:1127\u20131130. https:\/\/doi.org\/10.1007\/s12045-022-1409-z","journal-title":"Resonance"},{"key":"1447_CR102","doi-asserted-by":"crossref","unstructured":"Lu J, Jiang F, Lu A, Zhang G (2016) Linkers having a crucial role in antibody\u2013drug conjugates. Int. J. Mol. Sci.17","DOI":"10.3390\/ijms17040561"},{"key":"1447_CR103","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ddtec.2018.10.001","volume":"30","author":"R Lyon","year":"2018","unstructured":"Lyon R (2018) Drawing lessons from the clinical development of antibody-drug conjugates. Drug Discov Today Technol 30:105\u2013109. https:\/\/doi.org\/10.1016\/j.ddtec.2018.10.001","journal-title":"Drug Discov Today Technol"},{"key":"1447_CR104","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.seminoncol.2014.08.001","volume":"41","author":"F Mack","year":"2014","unstructured":"Mack F, Ritchie M, Sapra P (2014) The next generation of antibody drug conjugates. Semin Oncol 41:637\u2013652. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.08.001","journal-title":"Semin Oncol"},{"key":"1447_CR105","doi-asserted-by":"publisher","DOI":"10.1021\/jm501649k","author":"A Maderna","year":"2014","unstructured":"Maderna A, Doroski M, Subramanyam C, Porte A, Leverett C, Vetelino B, Cheng Z, Risley H, Parris K, Pandit J, Varghese A, Shanker S, Song C, Sukuru S, Farley K, Wagenaar M, Shapiro M, Musto S, Lam M, O\u2019Donnell C (2014) Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem. https:\/\/doi.org\/10.1021\/jm501649k","journal-title":"J Med Chem"},{"key":"1447_CR106","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3233\/HAB-2009-0204","volume":"18","author":"J Majidi","year":"2009","unstructured":"Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y (2009) Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 18:81\u2013100. https:\/\/doi.org\/10.3233\/HAB-2009-0204","journal-title":"Hum Antibodies"},{"key":"1447_CR107","doi-asserted-by":"publisher","first-page":"A819","DOI":"10.1136\/jitc-2021-SITC2021.784","volume":"9","author":"W Mallet","year":"2021","unstructured":"Mallet W, Gadkari R, Pearson C, Dulgeroff L, Luo A, Luo AA, Melrose J, Nolin J, Lee A, Zhou M, Anand P, Sarma G, Henning K, Blum L, Chapin S, Bogaert L, Ackerman S, Kudirka R, Shen Y, Dornan D (2021) 784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors. J Immunother Cancer 9:A819\u2013A819. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.784","journal-title":"J Immunother Cancer"},{"key":"1447_CR108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ddtec.2018.09.003","volume":"30","author":"A Maruani","year":"2018","unstructured":"Maruani A (2018) Bispecifics and antibody\u2013drug conjugates: a positive synergy. Drug Discov Today Technol 30:55\u201361. https:\/\/doi.org\/10.1016\/j.ddtec.2018.09.003","journal-title":"Drug Discov Today Technol"},{"key":"1447_CR109","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1248\/cpb.c21-00258","volume":"69","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Mendelsohn BA (2021) Recent advances in drug\u2013antibody ratio determination of antibody\u2013drug conjugates. Chem Pharm Bull 69:976\u2013983. https:\/\/doi.org\/10.1248\/cpb.c21-00258","journal-title":"Chem Pharm Bull"},{"key":"1447_CR110","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/imr.12390","volume":"270","author":"R Mazor","year":"2016","unstructured":"Mazor R, Onda M, Pastan I (2016) Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev 270:152\u2013164. https:\/\/doi.org\/10.1111\/imr.12390","journal-title":"Immunol Rev"},{"key":"1447_CR111","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC (2015) Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 17:339\u2013351. https:\/\/doi.org\/10.1208\/s12248-014-9710-8","journal-title":"AAPS J"},{"key":"1447_CR112","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/protein\/gzl013","volume":"19","author":"C Mcdonagh","year":"2006","unstructured":"Mcdonagh C, Turcott E, Westendorf L, Webster J, Alley S, Kim K, Andreyka J, Stone I, Hamblett K, Francisco J, Carter P (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19:299\u2013307. https:\/\/doi.org\/10.1093\/protein\/gzl013","journal-title":"Protein Eng Des Sel"},{"key":"1447_CR113","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","volume":"9","author":"CM Mckertish","year":"2021","unstructured":"Mckertish CM, Kayser V (2021) Advances and limitations of antibody drug conjugates for cancer. Biomedicines 9:872. https:\/\/doi.org\/10.3390\/biomedicines9080872","journal-title":"Biomedicines"},{"key":"1447_CR114","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1021\/acs.bioconjchem.6b00530","volume":"28","author":"BA Mendelsohn","year":"2017","unstructured":"Mendelsohn BA, Barnscher SD, Snyder JT, An Z, Dodd JM, Dugal-Tessier J (2017) Investigation of hydrophilic auristatin derivatives for use in antibody drug conjugates. Bioconjug Chem 28:371\u2013381. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00530","journal-title":"Bioconjug Chem"},{"key":"1447_CR115","doi-asserted-by":"publisher","first-page":"252","DOI":"10.37349\/etat.2022.00082","volume":"3","author":"S Menon","year":"2022","unstructured":"Menon S, Parakh S, Scott A, Gan H (2022) Antibody-drug conjugates: beyond current approvals and potential future strategies. Explor Target anti-tumor Ther 3:252\u2013277. https:\/\/doi.org\/10.37349\/etat.2022.00082","journal-title":"Explor Target anti-tumor Ther"},{"key":"1447_CR116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/acs.bioconjchem.5b00618","volume":"27","author":"C Meyer","year":"2016","unstructured":"Meyer C, Liebscher S, Bordusa F (2016) Selective coupling of click anchors to proteins via trypsiligase. Bioconjug Chem 27:47\u201353. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00618","journal-title":"Bioconjug Chem"},{"key":"1447_CR117","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2019","unstructured":"Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S, Lee K, Hurvitz S, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I (2019) Trastuzumab Deruxtecan in previously treated HER2-Positive breast Cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"1447_CR118","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P M\u00fcller","year":"2014","unstructured":"M\u00fcller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka H-M, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A (2014) Microtubule-depolymerizing agents used in antibody\u2013drug conjugates induce Antitumor Immunity by Stimulation of dendritic cells. Cancer Immunol Res 2:741\u2013755. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0198","journal-title":"Cancer Immunol Res"},{"key":"1447_CR119","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4939-9929-3_3","volume-title":"Conjugations to endogenous cysteine residues: antibody-drug conjugates","author":"DV Nadkarni","year":"2020","unstructured":"Nadkarni DV (2020) Conjugations to endogenous cysteine residues: antibody-drug conjugates. Springer, pp 37\u201349"},{"key":"1447_CR120","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.euf.2021.02.006","volume":"7","author":"JT Nauseef","year":"2021","unstructured":"Nauseef JT, Bander NH, Tagawa ST (2021) Emerging prostate-specific membrane Antigen-based therapeutics: small molecules, antibodies, and Beyond. Eur Urol Focus 7:254\u2013257. https:\/\/doi.org\/10.1016\/j.euf.2021.02.006","journal-title":"Eur Urol Focus"},{"key":"1447_CR121","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","volume":"80","author":"I Nessler","year":"2020","unstructured":"Nessler I, Khera E, Vance S, Kopp A, Qiu Q, Keating TA, Abu-Yousif AO, Sandal T, Legg J, Thompson L, Goodwin N, Thurber GM (2020) Increased tumor penetration of single-domain antibody\u2013drug Conjugates improves in vivo efficacy in prostate Cancer models. Cancer Res 80:1268\u20131278. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2295","journal-title":"Cancer Res"},{"key":"1447_CR122","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/1469066717733919","volume":"23","author":"R Neupane","year":"2017","unstructured":"Neupane R, Bergquist J (2017) Analytical techniques for the characterization of antibody drug conjugates: Challenges and prospects. Eur J Mass Spectrom 23:417\u2013426. https:\/\/doi.org\/10.1177\/1469066717733919","journal-title":"Eur J Mass Spectrom"},{"key":"1447_CR123","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, Cristofanilli M, Curigliano G (2022) Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev 106:102395. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102395","journal-title":"Cancer Treat Rev"},{"key":"1447_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2018.08.005","author":"A Pahl","year":"2018","unstructured":"Pahl A, Lutz C, Hechler T (2018) Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. https:\/\/doi.org\/10.1016\/j.ddtec.2018.08.005","journal-title":"Drug Discov Today Technol"},{"key":"1447_CR125","doi-asserted-by":"publisher","first-page":"103311","DOI":"10.1016\/j.drudis.2022.06.011","volume":"27","author":"G Pander","year":"2022","unstructured":"Pander G, Uhl P, K\u00fchl N, Haberkorn U, Anderl J, Mier W (2022) Antibody\u2013drug conjugates: what drives their progress? Drug Discov Today 27:103311. https:\/\/doi.org\/10.1016\/j.drudis.2022.06.011","journal-title":"Drug Discov Today"},{"key":"1447_CR126","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. MAbs 6:34\u201345. https:\/\/doi.org\/10.4161\/mabs.27022","journal-title":"MAbs"},{"key":"1447_CR127","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1039\/D0NJ04134C","volume":"45","author":"TK Patel","year":"2021","unstructured":"Patel TK, Adhikari N, Amin SA, Biswas S, Jha T, Ghosh B (2021) Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery. New J Chem 45:5291\u20135321. https:\/\/doi.org\/10.1039\/D0NJ04134C","journal-title":"New J Chem"},{"key":"1447_CR128","unstructured":"PEG BioPharma (2020) The history of ADC drugs development. https:\/\/www.biochempeg.com\/article\/125.html. Accessed 11 Aug 2022"},{"key":"1447_CR129","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM (2014) Antibody\u2013drug conjugates: current status and future directions. Drug Discov Today 19:869\u2013881. https:\/\/doi.org\/10.1016\/j.drudis.2013.11.004","journal-title":"Drug Discov Today"},{"key":"1447_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201900497","author":"T Pillow","year":"2019","unstructured":"Pillow T, Adhikari P, Blake R, Chen J, Rosario G, Deshmukh G, Figueroa I, Gascoigne K, Kamath A, Kaufman S, Kleinheinz T, Kozak K, Latifi B, Leipold D, Li C, Li R, Mulvihill M, O\u2019Donohue A, Rowntree R, Dragovich P (2019) Antibody conjugation of a chimeric BET degrader enables. Vivo Activity ChemMedChem. https:\/\/doi.org\/10.1002\/cmdc.201900497","journal-title":"Vivo Activity ChemMedChem"},{"key":"1447_CR131","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","volume":"69","author":"A Polson","year":"2009","unstructured":"Polson A, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage F, Eaton D, Elkins K, Elliott J, Frantz G, Fuji R, Gray A, Harden K, Ingle G, Kljavin N, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Stephan J, Scales S, Spencer S, Vandlen R, Wranik B, Yu S, Zheng B, Ebens A (2009) Antibody-drug conjugates for the treatment of non\u2013Hodgkin\u2019s lymphoma: target and linker-drug selection. Cancer Res 69:2358\u20132364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2250","journal-title":"Cancer Res"},{"key":"1447_CR132","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee J-L, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP (2021) Enfortumab Vedotin in previously treated Advanced Urothelial Carcinoma. N Engl J Med 384:1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"key":"1447_CR133","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1021\/acs.bioconjchem.5b00173","volume":"26","author":"PK Qasba","year":"2015","unstructured":"Qasba PK (2015) Glycans of antibodies as a specific site for drug conjugation using glycosyltransferases. Bioconjug Chem 26:2170\u20132175. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00173","journal-title":"Bioconjug Chem"},{"key":"1447_CR134","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/bmc.1345","volume":"24","author":"M Ramesh","year":"2010","unstructured":"Ramesh M, Ahlawat P, Srinivas NR (2010) Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr 24:104\u2013123. https:\/\/doi.org\/10.1002\/bmc.1345","journal-title":"Biomed Chromatogr"},{"key":"1447_CR135","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/ncponc0774","volume":"4","author":"A Ricart","year":"2007","unstructured":"Ricart A, Tolcher A (2007) Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4:245\u2013255. https:\/\/doi.org\/10.1038\/ncponc0774","journal-title":"Nat Clin Pract Oncol"},{"key":"1447_CR136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1517\/13543784.2014.908184","volume":"23","author":"T Robak","year":"2014","unstructured":"Robak T, Robak E (2014) Current phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 23:911\u2013924. https:\/\/doi.org\/10.1517\/13543784.2014.908184","journal-title":"Expert Opin Investig Drugs"},{"key":"1447_CR137","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nchembio.2416","volume":"13","author":"CB Rosen","year":"2017","unstructured":"Rosen CB, Francis MB (2017) Targeting the N terminus for site-selective protein modification. Nat Chem Biol 13:697\u2013705. https:\/\/doi.org\/10.1038\/nchembio.2416","journal-title":"Nat Chem Biol"},{"key":"1447_CR138","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-4939-9929-3_16","volume-title":"Conjugation site analysis of lysine-conjugated ADCs BT\u2014antibody-drug conjugates: methods and protocols","author":"H Sang","year":"2020","unstructured":"Sang H, Wan N, Lu G, Tian Y, Wang G, Ye H (2020). In: Tumey LN (ed) Conjugation site analysis of lysine-conjugated ADCs BT\u2014antibody-drug conjugates: methods and protocols. Springer, New York, pp 235\u2013250"},{"key":"1447_CR139","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","volume":"22","author":"S Sau","year":"2017","unstructured":"Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK (2017) Advances in antibody\u2013drug conjugates: a new era of targeted cancer therapy. Drug Discov Today 22:1547\u20131556","journal-title":"Drug Discov Today"},{"key":"1447_CR140","first-page":"2616","volume":"63","author":"A Savinainen","year":"2022","unstructured":"Savinainen A, Kines R, Rich CC (2022) A first in class Virus-Like Drug Conjugate (VDC) shows anti-tumor activity in cancers that commonly metastasize to the Choroid. Invest Ophthalmol Vis Sci 63:2616","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1447_CR141","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1039\/9781839165153","volume":"81","author":"EA Savoy","year":"2021","unstructured":"Savoy EA, Olatunji FP, Yoon H, Mesbahi N, Knight JR, Berkman CE (2021) Acid-labile linkers. Chem Linkers Antibody-Drug Conjug 81:213. https:\/\/doi.org\/10.1039\/9781839165153","journal-title":"Chem Linkers Antibody-Drug Conjug"},{"key":"1447_CR142","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.esmoop.2021.100102","volume":"6","author":"F Schettini","year":"2021","unstructured":"Schettini F, Barbao P, Bras\u00f3-Maristany F, Galv\u00e1n P, Mart\u00ednez D, Par\u00e9 L, De Placido S, Prat A, Guedan S (2021) Identification of cell surface targets for CAR-T cell therapies and antibody\u2013drug conjugates in breast cancer. ESMO Open 6:100102. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100102","journal-title":"ESMO Open"},{"key":"1447_CR143","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0265-6","author":"D Schumacher","year":"2016","unstructured":"Schumacher D, Hackenberger C, Leonhardt H, Helma-Smets J (2016) Current status: site-specific antibody drug conjugates. J Clin Immunol. https:\/\/doi.org\/10.1007\/s10875-016-0265-6","journal-title":"J Clin Immunol"},{"key":"1447_CR144","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.xphs.2022.06.012","volume":"111","author":"B Shah","year":"2022","unstructured":"Shah B, Li M, Wypych J, Joubert MK, Zhang Z (2022) Observation of Heavy-Chain C-Terminal Amidation in Human endogenous IgG. J Pharm Sci 111:2445\u20132450. https:\/\/doi.org\/10.1016\/j.xphs.2022.06.012","journal-title":"J Pharm Sci"},{"key":"1447_CR145","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi R, de la Torre BG, Albericio F (2022) Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics 14:396. https:\/\/doi.org\/10.3390\/pharmaceutics14020396","journal-title":"Pharmaceutics"},{"key":"1447_CR146","doi-asserted-by":"publisher","first-page":"39291","DOI":"10.1038\/srep39291","volume":"6","author":"V Siegmund","year":"2016","unstructured":"Siegmund V, Piater B, Zakeri B, Eichhorn T, Fischer F, Deutsch C, Becker S, Toleikis L, Hock B, Betz UAK, Kolmar H (2016) Spontaneous isopeptide bond formation as a powerful tool for engineering site-specific antibody-drug conjugates. Sci Rep 6:39291. https:\/\/doi.org\/10.1038\/srep39291","journal-title":"Sci Rep"},{"key":"1447_CR147","first-page":"445","volume-title":"Antibody\u2013cytotoxic agent conjugates: preparation and characterization BT\u2014therapeutic antibodies: methods and protocols","author":"R Singh","year":"2009","unstructured":"Singh R, Erickson HK (2009). In: Dimitrov AS (ed) Antibody\u2013cytotoxic agent conjugates: preparation and characterization BT\u2014therapeutic antibodies: methods and protocols. Humana Press, Totowa, pp 445\u2013467"},{"key":"1447_CR148","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.biotechadv.2015.05.001","volume":"33","author":"AM Sochaj","year":"2015","unstructured":"Sochaj AM, \u015awiderska KW, Otlewski J (2015) Current methods for the synthesis of homogeneous antibody\u2013drug conjugates. Biotechnol Adv 33:775\u2013784. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.05.001","journal-title":"Biotechnol Adv"},{"key":"1447_CR149","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1021\/bc050201y","volume":"16","author":"MMC Sun","year":"2005","unstructured":"Sun MMC, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FGM, Ihle NC, Senter PD, Alley SC (2005) Reduction\u2014alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16:1282\u20131290. https:\/\/doi.org\/10.1021\/bc050201y","journal-title":"Bioconjug Chem"},{"key":"1447_CR150","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzx067","author":"D Sussman","year":"2018","unstructured":"Sussman D, Westendorf L, Meyer D, Leiske C, Anderson M, Okeley N, Alley S, Lyon R, Sanderson R, Carter P, Benjamin D (2018) Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Protein Eng Des Sel. https:\/\/doi.org\/10.1093\/protein\/gzx067","journal-title":"Protein Eng Des Sel"},{"key":"1447_CR151","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-319-13081-1_2","volume-title":"Payloads of antibody-drug Conjugates BT\u2014antibody-drug conjugates: the 21st century magic bullets for Cancer","author":"C Tan","year":"2015","unstructured":"Tan C (2015). In: Wang J, Shen W-C, Zaro JL (eds) Payloads of antibody-drug conjugates BT\u2014antibody-drug conjugates: the 21st century magic bullets for Cancer. Springer International Publishing, Cham, pp 11\u201322"},{"key":"1447_CR152","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fphar.2019.00373","volume":"10","author":"H Tang","year":"2019","unstructured":"Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W, Han Q, Wei M, Jin Y (2019) The analysis of key factors related to adcs structural design. Front Pharmacol 10:373. https:\/\/doi.org\/10.3389\/fphar.2019.00373","journal-title":"Front Pharmacol"},{"key":"1447_CR153","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andr\u00e8 F, Curigliano G (2020) HER2-Low breast Cancer: pathological and clinical Landscape. J Clin Oncol 38:1951\u20131962. https:\/\/doi.org\/10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"1447_CR154","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria J, Curigliano G (2022) Antibody\u2013drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 72:165\u2013182. https:\/\/doi.org\/10.3322\/caac.21705","journal-title":"CA Cancer J Clin"},{"key":"1447_CR155","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","volume":"337","author":"T Tedeschini","year":"2021","unstructured":"Tedeschini T, Campara B, Grigoletto A, Bellini M, Salvalaio M, Matsuno Y, Suzuki A, Yoshioka H, Pasut G (2021) Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. J Control Release 337:431\u2013447. https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.041","journal-title":"J Control Release"},{"key":"1447_CR156","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","volume":"7","author":"AC Tiberghien","year":"2016","unstructured":"Tiberghien AC, Levy J-N, Masterson LA, Patel NV, Adams LR, Corbett S, Williams DG, Hartley JA, Howard PW (2016) Design and synthesis of Tesirine, a clinical antibody\u2013drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett 7:983\u2013987. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00062","journal-title":"ACS Med Chem Lett"},{"key":"1447_CR157","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0","journal-title":"Protein Cell"},{"key":"1447_CR158","unstructured":"U.S.F.D.A (2022) FDA D.I.S.C.O. Burst edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-elahere-mirvetuximab-soravtansine-gynx-fra-positive-platinum. Accessed 31 Jan 2023"},{"key":"1447_CR159","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ddtec.2018.09.005","volume":"30","author":"SS van Berkel","year":"2018","unstructured":"van Berkel SS, van Delft FL (2018) Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discov Today Technol 30:3\u201310. https:\/\/doi.org\/10.1016\/j.ddtec.2018.09.005","journal-title":"Drug Discov Today Technol"},{"key":"1447_CR160","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4155\/tde-2016-0002","volume":"7","author":"M Vankemmelbeke","year":"2016","unstructured":"Vankemmelbeke M, Durrant L (2016) Third-generation antibody drug conjugates for cancer therapy\u2013a balancing act. Ther Deliv 7:141\u2013144. https:\/\/doi.org\/10.4155\/tde-2016-0002","journal-title":"Ther Deliv"},{"key":"1447_CR161","first-page":"222","volume-title":"Challenges and new frontiers in analytical characterization of antibody-drug conjugates","author":"A Wagh","year":"2018","unstructured":"Wagh A, Song H, Zeng M, Tao L, Das TK (2018) In: MAbs (ed) Challenges and new frontiers in analytical characterization of antibody-drug conjugates. Taylor & Francis, pp 222\u2013243"},{"key":"1447_CR162","first-page":"161","volume-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","author":"A Wakanka","year":"2011","unstructured":"Wakanka A, Chen Y, Gokarn Y, Jacobson FS (2011) In: MAbs (ed) Analytical methods for physicochemical characterization of antibody drug conjugates. Taylor & Francis, pp 161\u2013172"},{"key":"1447_CR163","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-9966-27-70","volume":"27","author":"HL Waldum","year":"2008","unstructured":"Waldum HL, Sandvik AK, Brenna E, Fossmark R, Qvigstad G, Soga J (2008) Classification of tumours. J Exp Clin Cancer Res 27:70. https:\/\/doi.org\/10.1186\/1756-9966-27-70","journal-title":"J Exp Clin Cancer Res"},{"key":"1447_CR164","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, Ou X, Fowler E, Ashman N, Takada Y, Isidro-Llobet A, Parker JS, Carroll JS, Spring DR (2021) Site-selective modification strategies in antibody\u2013drug conjugates. Chem Soc Rev 50:1305\u20131353. https:\/\/doi.org\/10.1039\/D0CS00310G","journal-title":"Chem Soc Rev"},{"key":"1447_CR165","first-page":"93","volume-title":"Factors involved in the design of cytotoxic payloads for antibody\u2013drug Conjugates BT - antibody-drug conjugates and immunotoxins: from pre-clinical development to therapeutic applications","author":"WC Widdison","year":"2013","unstructured":"Widdison WC, Chari RVJ (2013) In: Phillips GL (ed) Factors involved in the design of cytotoxic payloads for antibody\u2013drug Conjugates BT - antibody-drug conjugates and immunotoxins: from pre-clinical development to therapeutic applications. Springer, New York, pp 93\u2013115"},{"key":"1447_CR166","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.canlet.2016.08.003","volume":"381","author":"M Woitok","year":"2016","unstructured":"Woitok M, Klose D, Niesen J, Richter W, Abbas M, Stein C, Fendel R, Bialon M, P\u00fcttmann C, Fischer R (2016) The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. Cancer Lett 381:323\u2013330. https:\/\/doi.org\/10.1016\/j.canlet.2016.08.003","journal-title":"Cancer Lett"},{"key":"1447_CR167","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijmm.2008.08.003","volume":"299","author":"P Wolf","year":"2009","unstructured":"Wolf P, Els\u00e4sser-Beile U (2009) Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 299:161\u2013176. https:\/\/doi.org\/10.1016\/j.ijmm.2008.08.003","journal-title":"Int J Med Microbiol"},{"key":"1447_CR168","doi-asserted-by":"publisher","first-page":"107759","DOI":"10.1016\/j.intimp.2021.107759","volume":"96","author":"T Wu","year":"2021","unstructured":"Wu T, Zhu J (2021) Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications. Int Immunopharmacol 96:107759. https:\/\/doi.org\/10.1016\/j.intimp.2021.107759","journal-title":"Int Immunopharmacol"},{"key":"1447_CR169","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1002\/ange.201814215","volume":"131","author":"K Yamada","year":"2019","unstructured":"Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA (2019) AJICAP: affinity peptide mediated regiodivergent functionalization of native antibodies. Angew Chemie 131:5648\u20135653","journal-title":"Angew Chemie"},{"key":"1447_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K (2021) Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun 12:1\u201313. https:\/\/doi.org\/10.1038\/s41467-021-23793-7","journal-title":"Nat Commun"},{"key":"1447_CR171","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1021\/ja047749k","volume":"126","author":"J Yin","year":"2004","unstructured":"Yin J, Liu F, Li X, Walsh CT (2004) Labeling proteins with small molecules by site-specific posttranslational modification. J Am Chem Soc 126:7754\u20137755. https:\/\/doi.org\/10.1021\/ja047749k","journal-title":"J Am Chem Soc"},{"key":"1447_CR172","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1021\/acs.bioconjchem.1c00213","volume":"32","author":"J You","year":"2021","unstructured":"You J, Zhang J, Wang J, Jin M (2021) Cysteine-based coupling: challenges and solutions. Bioconjug Chem 32:1525\u20131534. https:\/\/doi.org\/10.1021\/acs.bioconjchem.1c00213","journal-title":"Bioconjug Chem"},{"key":"1447_CR173","doi-asserted-by":"publisher","first-page":"18494","DOI":"10.1021\/jacs.2c07594","volume":"144","author":"D Yuan","year":"2022","unstructured":"Yuan D, Zhang Y, Lim KH, Leung SKP, Yang X, Liang Y, Lau WCY, Chow KT, Xia J (2022) Site-selective lysine acetylation of human immunoglobulin G for immunoliposomes and bispecific antibody complexes. J Am Chem Soc 144:18494\u201318503","journal-title":"J Am Chem Soc"},{"key":"1447_CR174","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1039\/D1SC05243H","volume":"13","author":"N Zacharias","year":"2022","unstructured":"Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D, Dong E, Paluch M, Fischer D, Zheng K (2022) A homogeneous high-DAR antibody\u2013drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem Sci 13:3147\u20133160. https:\/\/doi.org\/10.1039\/D1SC05243H","journal-title":"Chem Sci"},{"key":"1447_CR175","doi-asserted-by":"publisher","first-page":"9106","DOI":"10.1039\/C8CS00537K","volume":"47","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Park K-Y, Suazo KF, Distefano MD (2018) Recent progress in enzymatic protein labelling techniques and their applications. Chem Soc Rev 47:9106\u20139136. https:\/\/doi.org\/10.1039\/C8CS00537K","journal-title":"Chem Soc Rev"},{"key":"1447_CR176","doi-asserted-by":"publisher","first-page":"106626","DOI":"10.1016\/j.leukres.2021.106626","volume":"108","author":"J Zhang","year":"2021","unstructured":"Zhang J, Jain A, Milhas S, Williamson DJ, Mysliwy J, Lodge A, Thirlway J, Al Nakeeb M, Miller A, Rabbitts TH (2021) An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells. Leuk Res 108:106626. https:\/\/doi.org\/10.1016\/j.leukres.2021.106626","journal-title":"Leuk Res"},{"key":"1447_CR177","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","volume":"10","author":"P Zhao","year":"2020","unstructured":"Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y (2020) Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B 10:1589\u20131600. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.012","journal-title":"Acta Pharm Sin B"},{"key":"1447_CR178","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2014.06.020","volume":"352","author":"L Zhou","year":"2014","unstructured":"Zhou L, Xu N, Sun Y, Liu X, Margaret (2014a) Targeted biopharmaceuticals for cancer treatment. Cancer Lett 352:145\u2013151. https:\/\/doi.org\/10.1016\/j.canlet.2014.06.020","journal-title":"Cancer Lett"},{"key":"1447_CR179","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/bc400505q","volume":"25","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, Park A, Busch M, Bird J, Zheng X, Simonds-Mannes H, Kim J, Gregory RC, Miller RJ, Brondyk WH, Dhal PK, Pan CQ (2014b) Site-specific antibody\u2013drug conjugation through Glycoengineering. Bioconjug Chem 25:510\u2013520. https:\/\/doi.org\/10.1021\/bc400505q","journal-title":"Bioconjug Chem"},{"key":"1447_CR180","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpha.2020.05.008","volume":"10","author":"X Zhu","year":"2020","unstructured":"Zhu X, Huo S, Xue C, An B, Qu J (2020) Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. J Pharm Anal 10:209\u2013220. https:\/\/doi.org\/10.1016\/j.jpha.2020.05.008","journal-title":"J Pharm Anal"},{"key":"1447_CR181","unstructured":"Zou S (2023) Directions for next generation antibody-drug conjugates. https:\/\/www.eposters.net\/poster\/directions-for-next-generation-antibody-drug-conjugates#. Accessed 31 Jan 2023"},{"key":"1447_CR182","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1039\/C2CC32412A","volume":"48","author":"K Zuberb\u00fchler","year":"2012","unstructured":"Zuberb\u00fchler K, Casi G, Bernardes GJL, Neri D (2012) Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. Chem Commun 48:7100\u20137102. https:\/\/doi.org\/10.1039\/C2CC32412A","journal-title":"Chem Commun"},{"key":"1447_CR183","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","volume":"38","author":"J Zugazagoitia","year":"2016","unstructured":"Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L (2016) Current challenges in cancer treatment. Clin Ther 38:1551\u20131566. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.026","journal-title":"Clin Ther"}],"updated-by":[{"DOI":"10.1007\/s12272-024-01502-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000}}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-023-01447-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T12:08:05Z","timestamp":1719403685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-023-01447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":183,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1447"],"URL":"https:\/\/doi.org\/10.1007\/s12272-023-01447-0","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12272-024-01502-4","URL":"https:\/\/doi.org\/10.1007\/s12272-024-01502-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Declared None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}